Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NRP2 siRNA
- Development stage
- Preclinical
- Lead developer
- University of Nebraska Medical Center
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
NRP2 siRNA is a small interfering RNA (siRNA) designed to silence the expression of Neuropilin-2 (NRP2), a receptor protein that is frequently upregulated in advanced prostate cancer. NRP2 has been identified as a key mediator of resistance to androgen receptor signaling inhibitors (ARSIs) such as enzalutamide. By knocking down NRP2 expression, the siRNA inhibits the nuclear translocation of NRP2 and its subsequent interaction with the androgen receptor (AR), which prevents the transcription of specific oncogenes. Preclinical research conducted by the University of Nebraska Medical Center and the University of Bonn indicates that NRP2 inhibition can sensitize treatment-refractory prostate cancer cells to enzalutamide, leading to increased apoptosis and reduced tumorigenicity.
- Other names
- Neuropilin-2 siRNANeuropilin2 siRNANeuropilin 2 siRNAsiNRP2siNRP-2siNRP 2
02
Targets
Neuropilin-2 messenger RNAPRR (Pattern recognition receptors)
Beyond the preview
Go deeper on NRP2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NRP2 siRNA.